SCHEDULE: Sujal Patel Boosts Nautilus Biotech Stake to 16.3%

Sujal Patel, a key insider, increased his beneficial ownership in Nautilus Biotechnology, Inc. to 16.3% through recent option grants and open market purchases.

Summary

• Sujal Patel, the Reporting Person, beneficially owns an aggregate of 21,249,965 shares of Nautilus Biotechnology, Inc. Common Stock.
• This represents 16.3% of the Issuer's outstanding shares, calculated based on 126,564,473 shares outstanding as of February 19, 2026, plus 3,788,733 shares from exercisable options held by Mr. Patel.
• Ownership includes 10,366,721 shares directly owned by Mr. Patel, 5,280,476 shares directly owned by PFV I, LLC (where Mr. Patel has sole voting and dispositive power), and 1,814,035 shares directly owned by the Sujal Patel 2020 Children's Trust (where Mr. Patel and his spouse share voting and dispositive power).
• Mr. Patel also holds options to purchase 3,788,733 shares, with 2,326,231 of these options vested and exercisable within 60 days of March 2, 2026.
• On March 2, 2026, Mr. Patel was granted an option to purchase an additional 650,000 shares of the Issuer's Common Stock.
• On March 4, 2026, Mr. Patel purchased 25,000 shares of the Issuer's Common Stock on the open market.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as increased insider ownership by a key individual like Sujal Patel typically reflects confidence in the company's future prospects and strategic direction.

Positives

• Increased insider ownership by Sujal Patel, a significant individual, indicates confidence in Nautilus Biotechnology's future prospects.
• The recent open market purchase of 25,000 shares by Mr. Patel demonstrates direct investment and belief in the company.
• The grant of 650,000 options to Mr. Patel further aligns his incentives with long-term shareholder value.

Future Outlook

The filing indicates that unvested options held by Sujal Patel will vest over time, subject to his continued service. Additionally, 100% of any unvested shares would immediately vest if his employment is terminated without cause or for good reason during a specific change-in-control window, aligning management incentives with potential future corporate events.

Management Comments

• Management's equity incentives are structured such that unvested options vest over time, contingent on continued service.
• A provision for 100% immediate vesting of unvested shares exists if employment is terminated without cause or for good reason during a specific change-in-control period.

Industry Context

StockSavvy.ai notes that increased insider ownership, particularly by a significant individual like Sujal Patel, can be a positive signal in the highly competitive biotechnology sector. It suggests a belief in the company's long-term prospects and technology, which is crucial for early-stage biotech firms like Nautilus Biotechnology that rely heavily on innovation and future product development.

Stakeholder Impact

• Shareholders: Increased insider ownership may instill confidence, potentially leading to positive sentiment regarding the company's future.
• Management/Employees: The vesting conditions, including accelerated vesting during a change of control, provide incentives and a degree of security for the Reporting Person.

Key Dates

Recommendation

The increase in Sujal Patel's beneficial ownership, including open market purchases and option grants, signals strong insider confidence in Nautilus Biotechnology. However, this Schedule 13D filing primarily details ownership changes and does not provide comprehensive financial performance data. A 'hold' recommendation is prudent, acknowledging the positive insider sentiment while awaiting further financial disclosures to assess the company's operational health and growth trajectory.

Keywords

Nautilus Biotechnology, Sujal Patel, Schedule 13D, Insider Ownership, Common Stock, Biotechnology, SEC Filing, Stock Purchase, Option Grant